1 st December, 2015. Melbourne, Australia.


Rhinomed Ltd (ASX:RNO), today announced the appointment of a new director and Chairman Mr Ron Dewhurst. Mr Dewhurst will join the board as Chairman of the company following Mr Martin Rogers decision to step down as Chairman and as a Director of the company.


Mr Rogers said “Over the past three years we have worked tirelessly on firstly turning the company around and then getting it poised for global growth. We are now there. I am extremely proud of what the team has achieved and believe now is the right time to hand the baton on.”


“Ron brings an extraordinary level of domestic and international experience having held senior leadership roles in some of the world’s largest financial and investment companies. Ron’s interest in and strong support of multiple Australian technology companies is also reflective of his deep belief in the value and power of Australian innovation. As one of our major shareholders I am delighted that someone of Ron’s caliber has decided to take on the role of Chairman during this exciting stage of the company’s growth.” said Mr Rogers.


Mr Dewhurst has spent 40 years spread across the Investment Banking and Asset Management Industries. He has lived approximately half of his career outside his native Australia working in Hong Kong, the United Kingdom and the United States of America. Mr Dewhurst started his career at Melbourne broking firm McCaughan Dyson going on to become CEO of what became ANZ McCaughan Ltd. In 1992 he joined J P Morgan where he ran the Asian and European equities divisions in Hong Kong and London before being appointed Head of Americas for J P Morgan Asset Management. In 2004 he was CEO of IOOF Holdings Ltd and from 2008 until 2013 he was Senior Executive Vice President and Head of Global Investment Managers for Legg Mason Inc based in the U.S.A.


Ron Dewhurst commented, “I would like to acknowledge Martin for his extraordinary efforts in putting Rhinomed on the map. The company now has its Mute and Turbine technology on global markets and an exciting clinical program in place. Martin has been an integral part in delivering these outcomes.


Download a copy of the announcement HERE.